Novartis receives FDA approval for Cosentyx for patients aged 12 and older

Novartis (NVS) announced today that Cosentyx received US Food and Drug Administration approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor for this population. The approval of a distinct biologic option for pediatric patients living with HS allows treatment to be tailored to the individual and establishes Cosentyx as a meaningful addition to the treatment landscape.